Redeye adjusts its fair value range for 2cureX following the exercised warrants that bring in some SEK 31.4m (before related costs) and increases the number of shares. Our Base Case is adjusted to SEK 23 per share, with a Bull and Bear Case of SEK 32 and SEK 11, respectively. We await the ASCO conference and the presentation of its finalized clinical trial before publishing an eventual update.